Funds holding Bicycle Therapeutics PLC
ISIN US0887861088 · United Kingdom · LEI 213800XKUI6R7GKC3E43
- Fund holders
- 22
- Of which ETFs
- 7 15 other funds
- Value held
- ≈ 10.3M $ 10.1M $ · 180.8K €
| Fund | Shares | Value | Weight in fund | |
|---|---|---|---|---|
| T. Rowe Price Health Sciences Fund, Inc. T. ROWE PRICE HEALTH SCIENCES FUND, INC. | 739,251 | 3.4M $ | 0.03 % | as of Mar 31, 2026 ↗ |
| SmallCap Fund Principal Funds, Inc | 516,100 | 2.4M $ | 0.12 % | as of Apr 30, 2026 ↗ |
| Old Westbury Small & Mid Cap Strategies Fund Old Westbury Funds Inc | 265,973 | 1.3M $ | 0.01 % | as of Apr 30, 2026 ↗ |
| iShares Biotechnology ETF iShares Trust | 244,101 | 1.1M $ | 0.01 % | as of Mar 31, 2026 ↗ |
| T. Rowe Price Health Sciences Portfolio T. ROWE PRICE EQUITY SERIES, INC. | 62,846 | 291.6K $ | 0.04 % | as of Mar 31, 2026 ↗ |
| SmallCap Account Principal Variable Contract Funds, Inc | 45,500 | 211.1K $ | 0.12 % | as of Mar 31, 2026 ↗ |
| ALPS Medical Breakthroughs ETF ALPS ETF TRUST | 44,503 | 255K $ | 0.18 % | as of Feb 28, 2026 ↗ |
| Virtus Biotech Clinical Trials Etf ETFis Series Trust I | 37,047 | 174.9K $ | 0.47 % | as of Apr 30, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) International Small Cap ETF SPDR INDEX SHARES FUNDS | 30,512 | 141.6K $ | 0.02 % | as of Mar 31, 2026 ↗ |
| VOYA MULTI-MANAGER INTERNATIONAL SMALL CAP FUND Voya Mutual Funds | 30,052 | 141.8K $ | 0.02 % | as of Apr 30, 2026 ↗ |
| Health Sciences Trust John Hancock Variable Insurance Trust | 25,602 | 118.8K $ | 0.05 % | as of Mar 31, 2026 ↗ |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 25,129 | 144K $ | 0.00 % | as of Feb 28, 2026 ↗ |
| EQ/T.Rowe Price Health Sciences Portfolio EQ Advisors Trust | 20,819 | 96.6K $ | 0.06 % | as of Mar 31, 2026 ↗ |
| Horizon Kinetics Medical ETF Listed Funds Trust | 13,188 | 61.2K $ | 0.34 % | as of Mar 31, 2026 ↗ |
| Steward Values Enhanced International Fund Steward Funds Inc | 11,209 | 52.9K $ | 0.02 % | as of Apr 30, 2026 ↗ |
| Invesco NASDAQ Future Gen 200 ETF Invesco Exchange-Traded Fund Trust II | 8,851 | 50.7K $ | 0.36 % | as of Feb 28, 2026 ↗ |
| Harbor International Core Fund HARBOR FUNDS | 6,102 | 28.8K $ | 0.00 % | as of Apr 30, 2026 ↗ |
| TIFF MULTI-ASSET FUND TIFF Investment Program | 3,375 | 15.7K $ | 0.00 % | as of Mar 31, 2026 ↗ |
| Invesco Nasdaq Biotechnology ETF Invesco Exchange-Traded Fund Trust II | 2,589 | 14.8K $ | 0.02 % | as of Feb 28, 2026 ↗ |
| ProShares Ultra Nasdaq Biotechnology ProShares Trust | 2,136 | 12.2K $ | 0.01 % | as of Feb 28, 2026 ↗ |
| Blackstone Alternative Multi-Strategy Fund Blackstone Alternative Investment Funds | 1,100 | 5.1K $ | 0.00 % | as of Mar 31, 2026 ↗ |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 180.8K € | 0.22 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Virtus Biotech Clinical Trials Etf ETFis Series Trust I | 0.47 % | as of Apr 30, 2026 ↗ |
| Invesco NASDAQ Future Gen 200 ETF Invesco Exchange-Traded Fund Trust II | 0.36 % | as of Feb 28, 2026 ↗ |
| Horizon Kinetics Medical ETF Listed Funds Trust | 0.34 % | as of Mar 31, 2026 ↗ |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 0.22 % | as of Dec 31, 2025 ↗ |
| ALPS Medical Breakthroughs ETF ALPS ETF TRUST | 0.18 % | as of Feb 28, 2026 ↗ |
| SmallCap Account Principal Variable Contract Funds, Inc | 0.12 % | as of Mar 31, 2026 ↗ |
| SmallCap Fund Principal Funds, Inc | 0.12 % | as of Apr 30, 2026 ↗ |
| EQ/T.Rowe Price Health Sciences Portfolio EQ Advisors Trust | 0.06 % | as of Mar 31, 2026 ↗ |
| Health Sciences Trust John Hancock Variable Insurance Trust | 0.05 % | as of Mar 31, 2026 ↗ |
| T. Rowe Price Health Sciences Portfolio T. ROWE PRICE EQUITY SERIES, INC. | 0.04 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 21 | -9 | 2,135,985 | -39.3 % |
| 2026Q1 | 30 | +1 | 3,518,327 | -3.0 % |
| 2025Q4 | 29 | +1 | 3,626,494 | +3.9 % |
| 2025Q3 | 28 | -2 | 3,488,796 | +4.8 % |
| 2025Q2 | 30 | 0 | 3,329,996 | -0.9 % |
| 2025Q1 | 30 | -3 | 3,360,163 | -2.0 % |
| 2024Q4 | 33 | +5 | 3,428,512 | +59.3 % |
| 2024Q3 | 28 | 0 | 2,151,610 | +40.3 % |
| 2024Q2 | 28 | +8 | 1,533,069 | +62.5 % |
| 2024Q1 | 20 | -1 | 943,511 | -17.3 % |
| 2023Q4 | 21 | 1,140,740 |
Institutional managers
97 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| BAKER BROS. ADVISORS LP | 10,885,357 | 50.5M $ | as of Mar 31, 2026 |
| FCPM III SERVICES B.V. | 3,468,430 | 16.1M $ | as of Mar 31, 2026 |
| ARMISTICE CAPITAL, LLC | 3,398,000 | 15.8M $ | as of Mar 31, 2026 |
| Long Focus Capital Management, LLC | 3,310,687 | 15.4M $ | as of Mar 31, 2026 |
| ACADIAN ASSET MANAGEMENT LLC | 1,968,025 | 9.1K $ | as of Mar 31, 2026 |
| Siren, L.L.C. | 1,560,882 | 7.2M $ | as of Mar 31, 2026 |
| GSK plc | 1,529,561 | 7.1M $ | as of Mar 31, 2026 |
| PRINCIPAL FINANCIAL GROUP INC | 1,174,625 | 5.5M $ | as of Mar 31, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1,028,243 | 4.8K $ | as of Mar 31, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | 979,300 | 4.5M $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 618,327 | 2.9M $ | as of Mar 31, 2026 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 615,833 | 2.7M $ | as of Mar 31, 2026 |
| DIADEMA PARTNERS LP | 476,424 | 2.2M $ | as of Mar 31, 2026 |
| Birchview Capital, LP | 463,599 | 2.2M $ | as of Mar 31, 2026 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | 428,684 | 2M $ | as of Mar 31, 2026 |
| MARSHALL WACE, LLP | 377,335 | 1.8M $ | as of Mar 31, 2026 |
| CITADEL ADVISORS LLC | 377,085 | 1.7M $ | as of Mar 31, 2026 |
| Qube Research & Technologies Ltd | 308,617 | 1.4M $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 283,986 | 1.3M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 278,992 | 1.3M $ | as of Mar 31, 2026 |
| MOORE CAPITAL MANAGEMENT, LP | 275,000 | 1.3M $ | as of Mar 31, 2026 |
| Rangeley Capital, LLC | 232,260 | 1.1M $ | as of Mar 31, 2026 |
| JANE STREET GROUP, LLC | 218,115 | 1M $ | as of Mar 31, 2026 |
| Palo Alto Investors LP | 201,890 | 936.8K $ | as of Mar 31, 2026 |
| Eversept Partners, LP | 190,715 | 884.9K $ | as of Mar 31, 2026 |
Declared shareholders of Bicycle Therapeutics PLC
There are 3 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Armistice Capital, LLC and 1 other | 6.75 % | 3,398,000 | as of Mar 31, 2026 · SCHEDULE 13G |
| LONG FOCUS CAPITAL MANAGEMENT, LLC and 1 other | 6.60 % | 3,310,687 | as of Mar 31, 2026 · SCHEDULE 13G |
| Invus Public Equities, L.P. and 7 others | 3.10 % | 1,560,882 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding Bicycle Therapeutics PLC". https://titelia.com/en/stocks/bicycle-therapeutics-plc-US0887861088